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ABSTRACT
Primary vesicoureteric reflux accounts for approximately 10% of kidney failure requiring dialysis or
transplantation, and sibling studies suggest a large genetic component. Here, we report a whole-
genome linkage and association scan in primary, nonsyndromic vesicoureteric reflux and reflux nephrop-
athy. We used linkage and family-based association approaches to analyze 320 white families (661
affected individuals, generally from families with two affected siblings) from two populations (United
Kingdom and Slovenian). We found modest evidence of linkage but no clear overlap with previous
studies. We tested for but did not detect association with six candidate genes (AGTR2, HNF1B, PAX2,
RET, ROBO2, and UPK3A). Family-based analysis detected associations with one single-nucleotide
polymorphism (SNP) in the UK families, with three SNPs in the Slovenian families, and with three SNPs
in the combined families. A case-control analysis detected associations with three additional SNPs. The
results of this study, which is the largest to date investigating the genetics of reflux, suggest that major
loci may not exist for this common renal tract malformation within European populations.
J Am Soc Nephrol 21: 113–123, 2010. doi: 10.1681/ASN.2009060624
Vesicoureteric reflux (VUR) is abnormal move-
ment of urine from the bladder retrogradely
through the vesicoureteric junctions into the upper
urinary tract. This is a study of primary VUR, i.e.,
VUR that is not secondary to bladder outflow ob-
struction caused by neurogenic damage or urethral
valves or part of a multiorgan syndrome. VUR is
usually a benign condition but can be associated
with transient kidney damage, acute inflammation
from ascending pyelonephritis, or permanent dam-
age as a consequence of scarring after infection
and/or congenital kidney defects histologically
comprising renal hypoplasia (too few nephrons)
and/or renal dysplasia (incomplete differentia-
tion).1–3 These renal defects are grouped under the
term reflux nephropathy (RN). In the United King-
dom, RN accounts for 12% of the approximately
40,000 adults and 7% of the 768 children who re-
quire renal transplantation and/or life-long dialy-
sis.4
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Traditionally, the diagnosis of VUR has been based on cys-
tography with radiodense or radioisotopic materials to visual-
ize retrograde passage of urine. Williams et al.3 reviewed 15
cystography studies in well children: The largest study reported
no VUR in 722 children, whereas some of the smaller studies
reported much higher percentages of affected individuals. The
true prevalence of (primary) VUR in children remains uncer-
tain: 1% is probably conservative, and 10 to 20% is possible.3
Screening studies of first-degree relatives of individuals with
VUR identifies reflux in one third to one half of siblings5,6 and
65% of offspring.7 Futhermore, there is a high concordance of
primary VUR in identical twins,8 and families have been iden-
tified with multiple generations affected by primary VUR and
RN.9 Collectively, these studies suggest that there is a substan-
tial genetic component to VUR.
The first genome-wide linkage analysis for VUR, based on
seven kindreds,9 provided preliminary evidence for a locus on
chromosome 1 and also for genetic heterogeneity. In this
study, multipoint parametric and nonparametric linkage anal-
ysis was undertaken; however, one of the markers defining the
interval on chromosome 1, GATA176C01, was subsequently
found to be on chromosome 2 (Ensembl release 55, July 2009),
so this localization should be treated with caution. Subsequent
studies using similar kindreds10 –12 have supported the notion
that the condition is genetically heterogeneous. In the largest
linkage study of VUR before this report, Kelly et al.13 per-
formed a linkage genome scan of 609 individuals (283 affected
individuals in 129 families) and detected six to seven regions
with suggestive evidence of linkage,14 one of which at chromo-
some 2q37 attained genome-wide significance when analyzed
in a phenotypically derived subset of the data. The high inci-
dence in offspring of affected individuals and the large number
of pedigrees consistent with autosomal dominant inheritance,
albeit with reduced penetrance, is in keeping with a dominant
model; however, recently, a locus was identified on 12p11-q13
using a recessive model.15
Here we report on linkage and association analysis in af-
fected sibling pairs from two populations. We used the Af-
fymetrix NspI array to generate genome-wide data, adding in
haplotype-tagging single-nucleotide polymorphisms (SNPs)
to obtain full coverage for six candidate genes: AGTR2,
HNF1B, PAX2, RET, ROBO2, and UPK3A.16
RESULTS
Linkage Analysis
Disease status was initially coded as positive for cases with VUR
and/or RN. Supplemental Figures 1 through 4 show the non-
parametric linkage analysis results and information content
across the genome for the UK (348 cases in 172 families), Slo-
venian (313 cases in 148 families), and combined (661 cases in
320 families) samples, respectively. Table 1 shows all results
reaching a significance threshold of equivalent logarithm of
odds (LOD) score .1.17 The linkage analysis was repeated for
the UK and combined data coding disease status as positive
only when there was documented VUR (302 UK cases), that is,
excluding cases that had RN without documented VUR (for
the Slovenian data set, positive disease status for the original
313 cases already corresponded solely to VUR). The linkage
results were very similar to those found using the wider phe-
notype definition (data not shown); however, the peaks on
chromosome 6 in the UK data set and on chromosomes 10 and
11 in the combined data set all increased in significance
(LOD 5 2.35, P 5 0.0005 at rs863820 on chromosome 6;
LOD 5 2.32, P 5 0.0005 at rs7904367 at 160.38 cM on chro-
mosome 10; and LOD 5 2.27, P 5 0.0006 at rs9733150 on
chromosome 11). The linkage analysis was also repeated for a
separate subset of the UK families (132 families, 212 cases) in
which disease status corresponded to being positive for RN.
Only one peak with LOD .2 was observed (LOD 5 2.02, P 5
0.001), at rs1860436 on chromosome 12.
We also carried out parametric linkage analysis (allowing
for heterogeneity) under fully penetrant recessive and domi-
nant models. The results (with disease coded as positive for
cases with VUR and/or RN) are shown in Table 2. Several peak
heterogeneity LODs (HLODs) occur close to nonparametric
linkage analysis peaks, but, in addition, under a recessive
model, we found three new peaks: In the Slovenian data,
HLOD 5 2.72 at rs2162769, and in the combined data,
HLOD 5 3.02 at rs484936 and HLOD 5 2.87 at rs475188. Also
in the UK data, rs928720, which showed weak significance
(LOD 5 1.46) in nonparametric analysis, showed stronger sig-
nificance (HLOD 5 3.12) in parametric analysis under a reces-
sive model.
Association Analysis
The significant results from the family-based association stud-
ies (using SNPs passing medium, stringent, or very stringent
quality control [QC] thresholds) are shown in Table 3. Figure
1 shows a Manhattan plot of the genome-wide results from the
transmission disequilibrium test (TDT) analysis using a medi-
um-stringency SNP selection criterion. Figures 2 through 4
show quantile-quantile (Q-Q) plots18 of the TDT statistics ob-
tained in the UK, Slovenian, and combined data sets at differ-
ent levels of stringency of SNP selection. Results are shown
with or without use of a robust clustered sandwich estimator of
the variance19,20 to correct for any nonindependence between
related individuals. In the UK data set, little evidence is seen for
association at the very stringent, stringent, or medium thresh-
olds, beyond what is expected from genome-wide testing. The
top-ranked SNP at the medium threshold is rs11083021 on
chromosome 18 (P 5 3.06 3 1026). In the Slovenian data set,
at the very stringent criterion, two SNPs on chromosome 5
(rs17144806 and rs4895183) show significance beyond what is
expected from genome-wide testing (P 5 5.81 3 1027 and P 5
2.55 3 1026, respectively). A third SNP (rs16963279 on chro-
mosome 18) shows significance (P 5 3.13 3 1026) at the me-
dium criterion. In the combined data set, at the very stringent
SNP selection criterion, little evidence is seen for association,
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but two SNPs show significance at the stringent criterion
(rs11029158 on chromosome 11 [P 5 1.82 3 1026] and
rs1696803 on chromosome 10 [P 5 2.25 3 1026]). These are
joined by a third (rs2102860 on chromosome 3; P 5 7.43 3
1027) at the medium criterion. Interestingly, this SNP lies only
approximately 2.2 Mb from the modest linkage peak (LOD 5
1.411) seen at rs7635068 in the combined data set.
Family-based association analysis for the UK and combined
data was repeated using the subset of 615 from the original 661
cases in which disease status was coded as positive for VUR,
rather than positive for VUR and/or RN (see Supplemental
Figures 5 and 6). For the UK data, there is little evidence for
association (beyond what is expected from genome-wide test-
ing) at any SNP selection criterion, although the top-ranked
SNPs remain the same as when using the wider phenotype
definition. For the combined data, the same top-ranked SNPs
are identified at the stringent and medium criteria as were
identified using the wider phenotype definition (rs11029158
on chromosome 11 [P 5 2.7 3 1027], rs1696803 on chromo-
some 10 [P 5 5.27 3 1026] and rs2102860 on chromosome 3
[P 5 3.5 3 1027]); however, interestingly, with the narrower
phenotype definition, these results show increased significance
and better separation in the Q-Q plots from the bulk of the
results that lie on the straight line with slope 1. We also re-
peated the association analysis for a separate subset of the UK
families (132 families, 212 cases) in which disease status corre-
sponded purely to being positive for RN but found nothing of
significance
Supplemental Figures 7 and 8 show Q-Q plots from the
family-based analysis of chromosome X SNPs using UN-
PHASED.21 Although none reach genome-wide significance
thresholds, it is notable that two SNPs (rs1983167 and
rs7881785) passing the very stringent QC threshold show clear
departure from the theoretical x2 distribution (P 5 5.22 3
1025 and P 5 6.97 3 1025, respectively, in the combined [UK
and Slovenian]) data). We found no significant associations
with any of the SNPs in AGTR2, HNF1B, PAX2, RET, ROBO2,
or UPK3A in either the UK or Slovenian data sets, taking into
account the multiple tests (146 tests) performed.
Table 4 shows the significant results from our case-control
(SNPTEST and STATA logistic regression) analyses at all SNPs
passing the medium QC threshold, using our UK VUR cases
together with 2938 Wellcome Trust Case Control Consortium
(WTCCC) controls. We used genomic control22 to adjust our
Table 1. Nonparametric linkage analysis results (all regions with LOD .1)
Population SNP (Affy ID) rsID Chromosome Position (cM) LOD P
UK SNP_A-1987308 rs665691 1 41.418 1.064 0.0134
SNP_A-2279980 rs645490 2 32.903 2.334 0.0005
SNP_A-2289125 rs863820 6 147.510 1.451 0.0049
SNP_A-2053466 rs819188 8 41.833 1.171 0.0101
SNP_A-1835216 rs4751955 10 135.942 1.413 0.0054
SNP_A-2236448 rs2762130 13 50.435 1.490 0.0044
SNP_A-1970159 rs2834819 21 41.632 1.092 0.0125
SNP_A-2014906 rs2499416 X 105.135 1.029 0.0147
Slovenian SNP_A-1860017 rs4665856 2 49.453 1.276 0.0077
SNP_A-2009329 rs4894708 3 180.583 1.552 0.0038
SNP_A-2264782 rs1123037 4 150.575 1.271 0.0078
SNP_A-2139359 rs4307059 5 45.367 1.342 0.0065
SNP_A-1886953 rs6605523 6 187.786 2.213 0.0007
SNP_A-2025716 rs12338022 9 85.707 1.058 0.0137
SNP_A-2006435 rs1368532 10 154.661 1.225 0.0088
SNP_A-4223649 rs451041 11 3.929 1.383 0.0058
SNP_A-2235976 rs10792438 11 86.984 2.490 0.0004
SNP_A-2103717 rs17795514 14 19.591 1.923 0.0017
SNP_A-2246580 rs9895463 17 55.513 1.009 0.0155
SNP_A-2018900 rs9977677 21 43.627 1.523 0.0040
SNP_A-2061492 rs11798108 X 27.452 2.012 0.0012
UK 1 Slovenian combined SNP_A-2279980 rs645490 2 32.903 2.227 0.0007
SNP_A-1873043 rs1304514 2 189.214 1.268 0.0078
SNP_A-2190940 rs7635068 3 197.985 1.411 0.0054
SNP_A-2149193 rs9364703 6 176.067 1.200 0.0068
SNP_A-2197430 rs601223 7 69.891 1.253 0.0082
SNP_A-2054876 rs2457426 8 40.707 1.386 0.0058
SNP_A-2006435 rs1368532 10 154.661 1.551 0.0038
SNP_A-2191227 rs9733150 11 87.935 2.032 0.0011
SNP_A-2121427 rs10773541 12 156.377 1.099 0.0122
SNP_A-2018900 rs9977677 21 43.627 2.637 0.0002
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SNPTEST results for inflation as a result of relatedness between
cases (see Supplemental Figure 9 for Q-Q plots and details of
adjustment for related cases). We used a robust clustered sand-
wich estimator of the variance to adjust for relatedness in
STATA.19,20 Overall, there was close correspondence between
the top-ranking results from the STATA logistic regression
analysis and the SNPTEST analysis. The most significant re-
sults from the STATA analysis were rs1159217 on chromo-
some 10 (P 5 3.96 3 1027) and rs17306391 on chromosome
11 (P 5 5.67 3 1027) and from the SNPTEST analysis,
rs12604993 on chromosome 18 (P 5 2.38 3 1027).
DISCUSSION
We presented here the results from a genome-wide linkage and
association analysis in primary, nonsyndromic VUR and RN.
Parametric linkage analysis, which uses assumptions about the
mode of inheritance of the disease, is often used to map dis-
eases to genomic regions harboring the causative gene and has
been very successful in identifying genes for Mendelian disor-
ders.23–26 Nonparametric linkage analysis seeks genomic re-
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Figure 1. Manhattan plot of the TDT statistics using the medium
level of SNP selection stringency is shown.
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Figure 2. Q-Q plot of TDT statistics in UK data at different levels
of stringency of SNP selection is shown.
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gions where pairs or groups of affected relatives share more
alleles inherited by descent from their common ancestor(s)
than expected by chance, making no assumptions about mode
of inheritance. In common with many previous genome scans
in complex diseases, our nonparametric linkage analyses
found a number of regions showing modest linkage signals that
did not generally replicate across study groups (either our own
or previous studies12,13). Nonparametric linkage analysis of
VUR and/or RN identified one locus (on chromosome 2) with
LOD .2 in the UK cases, three loci (on chromosomes 6, 11,
and X) with LOD .2 in the Slovenian cases, and three loci (on
chromosomes 2, 11, and 21) with LOD .2 in the combined
data set, but no peaks with a LOD .3. The peak on chromo-
some 21 could correspond to a weakly significant result (P 5
0.006) in the study of Kelly et al.13 The very weak peak we
observed on chromosome 3 in the Slovenian data set could
correspond to a similarly weak result (P 5 0.003) in the study
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Figure 3. Q-Q plot of TDT statistics in Slovenian data at different
levels of stringency of SNP selection in shown.
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Figure 4. Q-Q plot of TDT statistics in combined (UK and Slov-
enian) data at different levels of stringency of SNP selection is
shown.
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of Kelly et al.13 Restricting analysis to those with documented
VUR increased the significance to LOD .2 for the peaks on
chromosome 6 in the UK data set and on chromosome 10 in
the combined data set. This is of interest because the chromo-
some 6 and chromosome 10 peaks could potentially corre-
spond to results (P 5 0.0003 and P 5 0.0005 respectively)
found in the study of Kelly et al.13
Parametric linkage analysis assuming a recessive disease
model provided stronger evidence for linkage at rs484936
(HLOD 5 3.02) on chromosome 3 and rs2835104 (HLOD 5
3.21) on chromsome 21 in the combined data set, at rs4669767
(HLOD 5 3.02) on chromosome 2 and rs928720 on chromo-
some 6 (HLOD 5 3.12) in the UK data set, and at rs2097171 on
chromosome 11 (HLOD 5 3.33) in the Slovenian data set.
Parametric linkage analysis assuming a dominant disease
model gave one HLOD .3, at rs9977677 on chromosome 21.
All of these linkage regions contain a large number of genes
(between 11 and 34 genes using an “HLOD minus 1” threshold
and between 23 and 131 genes using an “HLOD minus 2”
threshold). Although HLODs .3 are encouraging, the fact that
we have maximized the LOD score over two models (recessive
and dominant) as well as over a heterogeneity parameter a (the
proportion of linked families) means that we should interpret
these results cautiously. Abreu et al.27 suggested that, in these
circumstances, subtraction of 0.3 from the final HLOD would
be an appropriate correction.
We did not find linkage in the region on chromosome 12
reported by Weng et al.15 Seven families contributed to the
locus reported by Weng et al.: Four Hasidic Jewish, two Italian,
and an Irish American but with the major contribution coming
from two of the Hasidic Jewish families. The authors postu-
lated that this locus could be important in families of various
ethnic origins, but it does not seem to account for a significant
proportion of families in either of the populations we have
studied. The conclusion from our and previous linkage analy-
ses is that if rare familial mutations contribute to recurrence,
then many genes are likely to be involved and an alternative
approach to identifying these genes28 would be to screen for
rare mutations in genes regulating development of the urinary
tract, as has been done for genes coding for salt-handling mol-
ecules in the context of human blood pressure variation.29
Association studies allow one to test the contribution of
particular common alleles to disease. The TDT examines
transmission of alleles from heterozygous parents to affected
offspring: Under the null hypothesis, there should be no pref-
erential transmission of one allele over another, whereas under
the alternative hypothesis, the high-risk allele should be trans-
mitted more often to affected offspring. The TDT provides a
test that is robust to population stratification, unlike standard
case-control association analysis; however, the advantage of
additionally performing case-control analysis in our data is the
greater power that can potentially be achieved, first through
use of a larger control sample and second by the ascertainment
“bias” induced through the comparison of cases who have a
close relative (a sibling) who also has the disease, with standard
population control subjects.30 –32
A number of loci in the association analyses approached
genome-wide significance levels; however, there was relatively
little concordance in the results from our two study groups
(UK and Slovenian) or between the results from our linkage
and association analyses. This is not surprising given the rela-
tively small sample size of the individual population groups,
meaning that the power to detect small effects as conferred by
most risk alleles in complex diseases will be low.18 rs11083021
is in intron 3 of OSBPL1A, which encodes oxysterol-binding
protein–like 1A, a member of the OSBP family of intracel-
lular lipid receptors. The two chromsome 5 SNPs detected
in the Slovenian analysis, rs4895183 and rs17144806, and
rs17175928 and rs16963279 are intronic SNPs in genes of un-
known function, DTWD2, C10orf72, and FAM59A, respec-
tively. rs2102860 is in linkage disequilibrium (LD) with RTP4,
which encodes a Golgi chaperone that plays a role in move-
ment of m-d opioid receptor to the cell surface membrane33
and may be involved in membrane targetting of other G pro-
tein– coupled receptors. rs1983167 and rs7881785 both are in
LD with the monoamine oxidase inhibitors MAOA and
MAOB. rs12604993 is in LD with TXNL4A (thioredoxin-like
4A). Two SNPs identified in the family-based analysis,
rs1696803 and rs11029158, and two identified in the case-con-
trol analysis of the UK cases, rs11599217 and rs17306391, are
not in LD with transcripts.
We also tested for association with six candidate genes pre-
viously implicated in human renal tract development: AGTR2,
HNF1B, PAX2, RET, ROBO2, and UPK3A. Mutations have
been identified in ROBO2 and HNF1B in patients with urinary
tract malformations,34,35 but we found no evidence of an asso-
Table 4. Top-ranking results from case-control analysis performed using either SNPTEST (with or without the ‘-proper’
option) or logistic regression in STATA
SNP (Affy ID) rsID Chromosome
Physical
Position
cM
Associated
Allele
MAF
SNPTEST P
(-proper)
SNPTEST P
(without
-proper)
STATA P
SNP_A-1903023 rs11599217 10 128556954 158.28 Aa 0.39 2.98 3 1025 1.95 3 1025 3.96 3 1027
SNP_A-2235245 rs17306391 11 23147948 38.74 Ga 0.03 0.00051 1.17 3 1026 5.67 3 1027
SNP_A-2243575 rs12604993 18 75866208 121.56 Gb 0.19 2.38 3 1027 1.96 3 1026 2.82 3 1026
SNPTEST results are adjusted via genomic control to account for relatedness between individuals, whereas STATA results are adjusted through use of a robust
clustered sandwich estimator of the variance. MAF, minor allele frequency.
aMinor allele is associated with disease.
bMajor allele is associated with disease.
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ciation between common alleles in these genes and VUR in this
study. Yim et al.36 reported association between an AGTR2
intronic variant and diverse kidney malformations, although
this was not replicated in two studies.37,38 Yang et al.39 pre-
sented data for association with between a RET polymorphism
(p.Gly691Ser) and VUR, but this was not replicated in an Irish
cohort.40 Jiang et al.41 reported a weak association between a
UPK3A missense polymorphism and VUR. We have not de-
tected significant association with any of these genes and VUR
in the UK, Slovenian, or combined VUR patient groups.
The final size of our study (320 families, 661 affected indi-
viduals, 140,484 SNPs) is modest in size and genome coverage
is incomplete; nevertheless, it is by far the largest genetic study
of VUR to date. Given the small sample size of our collection,
our results should be interpreted with caution. Our genome-
wide association analyses are perhaps best considered as ex-
ploratory, the findings from which require replication in larger
cohorts. An obvious question regarding the association analy-
sis is what coverage of the genome was achieved. The Af-
fymetrix 500K SNP array set (consisting of two arrays, Sty and
Nsp) has been previously estimated42 to provide 65% coverage
of the genome at R2 5 0.8. This leaves a 35% chance that none
of the SNPs genotyped reaches this level of correlation with a
causal variant. Our study (conceived originally as a linkage
study) used only a single array from the 500K set (the Nsp
array), which approximately halves the number of SNPs geno-
typed. QC procedures reduced the number of SNPs still fur-
ther, reducing our coverage to levels that are probably closer to
the 31% provided by the Affymetrix 111K array.42 Increasing
sample size and conducting a whole-genome association scan
with a much denser array, taking advantage of recent improve-
ments in genotyping quality and genotype calling,43 an ap-
proach that has achieved recent success in other complex ge-
netic diseases,18,44 – 49 is the natural next step in testing whether
common variants contribute to VUR.
CONCISE METHODS
Sample Collection
The study, which adhered to the Declaration of Helsinki, was ap-
proved by UK Research Ethics Committees and the Slovenian Na-
tional Ethics Committee; informed consent was obtained before sam-
ple collection. In the United Kingdom, families were referred by
primary physicians from the UK VUR Study Group (listed in ac-
knowledgments). The inclusion criteria for UK families were an index
case with VUR diagnosed using x-ray cystography or radionuclide
cystography, together with an affected sibling with radiologically
proven VUR and/or RN demonstrated on DMSA scanning. Blood
samples were collected from affected siblings and their parents, and
DNA was extracted by standard procedures. The UK collection com-
prises 189 index cases with 219 affected siblings (161 sibling pairs, 26
families with three affected children, and two families with four af-
fected children). A total of 120 of the index cases had both VUR and
RN, 60 had VUR only, and information on RN was not available for
the remaining nine index cases; 77 of the siblings had both VUR and
RN, 78 had VUR only, 40 had RN only, and information on RN was
not available in the remaining 24 siblings with VUR.
Slovenian patients were identified from the database of children
who were referred to the Department of Pediatric Nephrology, Uni-
versity Medical Centre Ljubljana. Suitable families were identified by
screening the database for children who had VUR and for whom the
reason for investigation was a sibling with VUR. VUR was diagnosed
by voiding urosonography,50 radionuclide cystography, or, in a few
cases, x-ray cystography. Blood samples were collected from affected
siblings and their parents, and DNA was extracted by standard pro-
cedures. The Slovenian collection comprises 149 index cases with 169
affected siblings (133 sibling pairs, 13 families with three affected chil-
dren, two families with four affected children, and one family with five
affected children).
All of the cases we collected had primary VUR (i.e., there were no
cases with anatomic or neurogenic bladder outflow obstruction), and
we excluded families in which the index case or sibling had additional
structural defects in the urinary tract. In both the UK and Slovenian
collections, parental disease status was coded as unknown. Parental
DNA was genotyped in 612 parents from the 320 families. Three un-
affected siblings (from the UK collection) were also genotyped and
included in the linkage analysis.
DNA Analysis
Genotyping of the samples was carried out by the company Geneser-
vice, using the Affymetrix 262,264 SNP NspI array. Genotypes at the
262,264 SNPs were assigned (“called”) from the raw intensity data
using the CHIAMO algorithm.18 For the six candidate genes, we used
the Tagger option in the program Haploview to identify SNPs to
provide coverage at R2 5 0.8. This resulted in 101 SNPs for ROBO2,
12 for RET, 10 for PAX2, 17 for HNF1B, five for UPK3A, and three for
AGTR2 (Supplemental Table 1), and these were typed by Sequenom.
Quality Control
Stringent QC checks were used to ensure the accuracy of the final
genotype data and pedigree information (details in Supplemental in-
formation). The final number of samples remaining after all of the
sample QC checks had been carried out was 1282 (comprising 692 UK
samples and 590 Slovenian samples) in 320 families (172 UK families
and 148 Slovenian families) of an original 1398 samples genotyped.
We used these samples to re-perform QC measures on the SNPs, to
choose SNPs with the most reliable genotype calls for the final analy-
sis. We selected SNPs at five different levels of stringency, as shown in
Supplemental Table 2.
Linkage Analysis
We used SNPs passing the very stringent QC threshold to perform
multipoint nonparametric (model-free) linkage analysis across the
genome. For reasons of computational efficiency, we thinned our set
of SNPs to use a single SNP—that with the highest heterozygosity—in
each 1-cM window. Examination of the resulting information content
plots (Supplemental Figure 4) indicates that this thinned set of SNPs
provides adequate linkage information. We used the programs MER-
LIN and MINX51 to calculate information content and test for linkage
BASIC RESEARCH www.jasn.org
120 Journal of the American Society of Nephrology J Am Soc Nephrol 21: 113–123, 2010
using a multipoint “equivalent LOD score” to the Kong and Cox
exponential model likelihood-based allele-sharing test.17 We also
used MERLIN and MINX to perform parametric linkage analysis al-
lowing for heterogeneity (an “HLOD” analysis), assuming a disease
allele frequency of 0.01, under both recessive (penetrances 0.01, 0.01,
and 0.99) and dominant (penetrances 0.01, 0.99, and 0.99) models.27
Association Analysis
We used the TDT52 at each SNP passing our various QC filters. We
calculated the TDT using the R package DGCgenetics (1) assuming
each case/parent trio was an independent unit and (2) allowing for
nonindependence between related trios (e.g., affected sibling pairs)
through use of a robust clustered sandwich estimator of the vari-
ance.19,20 Significance was assessed through examination of Q-Q
plots,18 which is broadly equivalent to use of a Bonferroni correction
to assess the overall significance of a given result in light of the mul-
tiple tests performed.
The candidate gene SNPs were analyzed by TDT. Because analysis
of these genes was hypothesis driven, we did not apply the same mul-
tiple correction factor as already discussed but instead corrected for
the 146 independent tests.
For the UK cases, we additionally used the affected offspring (cases)
together with a sample of 2938 control subjects (genotyped at the same
SNPs by the WTCCC18) to perform case-control analysis. We used the
program SNPTEST18 to perform frequentist case-control association
tests at each SNP passing our medium QC filters, first using the default
options and then additionally allowing for genotype uncertainty via use
of the ‘-proper’ option within SNPTEST. We incorporated as covariates
in the analysis the first six principal components from a principal com-
ponents analysis performed using the ‘smartpca’ routine within the
EIGENSOFT package,53 using a set of 45,459 markers chosen to be in low
LD with one another (R2 ,0.2) and using only unrelated individuals (the
WTCCC control subjects and a single case from each VUR sibship) to
infer the eigenvectors, onto which the remaining individuals were then
projected. This approach has been previously proposed to adjust for pop-
ulation stratification.53 Logistic regression (incorporating the same six
covariates) in STATA was also performed at each SNP (1) assuming that
each case/parent trio was independent and (2) allowing for nonindepen-
dence between related cases through use of a robust clustered sandwich
estimator of the variance.19,20 We used genomic control22 to adjust our
SNPTEST results for inflation as a result of relatedness between cases.
We analyzed SNPs on chromosome X separately from the autoso-
mal SNPs, using, for the family data, a likelihood-based analysis as
implemented in the program UNPHASED21 and, for the case/control
data, logistic regression analysis including the first six principal com-
ponents as covariates as described already, with robust clustered vari-
ance estimates. The rationale for treating chromosome X SNPs sepa-
rately was that many of the methods and programs described already
for autosomal analysis are not directly applicable to X-linked loci.54
Visual assessment of the cluster plots18 on which genotype calls
were based (see supplemental information) was performed for SNPs
showing significant association with disease. All except one SNP
(rs16963279 on chromosome 18 from Table 3) showed reasonable
separation among the three genotype clusters. rs16963279 showed
only two genotype clusters, probably because the minor allele fre-
quency is sufficiently low that no homozygotes for the minor allele
were observed in our samples.
ACKNOWLEDGMENTS
This project was supported by the British Association for Pediatric
Nephrology (BAPN), the Medical Research Council (MRC) (Grant
reference G0600040), and the Wellcome Trust (Grant references
066647, 070327, and 074524).
Members of the UK VUR Study Group were Royal Victoria Infir-
mary, Newcastle upon Tyne: M. Coulthard, H. Lambert, E. Hunter,
M. Kier, N. Moghal, M. Ognanovic, S. Vernon; Cumberland Infir-
mary: J. Storr; West Cumberland Infirmary: J. Jackson; University
Hospital of North Tees: I. Verber; James Cook University Hosptal,
Middlesborough: S. Sinha; Leeds Teaching Hospitals NHS Trust: M.
Fitzpatrick, S. Feather; Royal Manchester’s Children’s Hospital: M.
Lewis, N. Webb, M. Bradbury, N. Plant, R. Postlethwaite, D.J.
O’Donoghue; Royal Liverpool Children’s Hospital: D. Hughes, C.
Jones, B. Judd; Royal Belfast Hospital for Sick Children: M. Savage, M.
O’Connor, M. Convery; Burnley General Hospital: J. Iqbal; Royal Hos-
pital for Sick Children, Glasgow: H. Maxwell, J. Beattie; Royal Hospital
for Sick Children, Edinburgh: S. Taheri; Great Ormond Street Hospital,
London: P. Cuckow, S. Marks, L. Rees, R. Trompeter, K. Tullus, W. Van’t
Hoff, D. Wilcox, A. Woolf; Evelina Children’s Hospital, London: G. Hay-
cock, C. Reid, S. Rigdon; Nottingham City Hospital: A. Watson; Bir-
mingham Children’s Hospital: S. Hulton, D. Milford, S. Stephens, C.M.
Taylor; Bristol Royal Hospital for Sick Children: J. Dudley, C. Inward, M.
McGraw, J. Tizard; University Hospital of Wales: K. Verrier-Jones; St.
Mary’s Hospital, Portsmouth: J. Scanlan; Leicester Royal Infirmary: P.
Houtman; Addenbrookes Hospital, Cambridge: R. Sandford; Queen
Elizabeth the Queen Mother Hospital, Margate: E. Rfidah; University
College Hospital, London: D. Hodes, A. Kilby; Walsgrave Hospital, Cov-
entry: N. Coad; Derriford Hospital, Plymouth: R. Jones; Gloucester Royal
Hospital: L. Jadresic; Northampton General Hospital: N. Griffin; Queen
Elizabeth Hospital, Kings Lynn: J. Dossetor, A. Hughes; Whittington
Hospital, London: M. Jaswon.
We thank Hin-Tak Leung, Jonathan Marchini, and Chris Spencer
for assistance with use of software developed by the WTCCC. We
thank and acknowledge the oversight provided to the collectors
through the VUR Development Group, led by Kidney Research UK,
which included representation from the wider research community
and the BAPN.
DISCLOSURES
None.
REFERENCES
1. Risdon RA, Yeung CK, Ransley PG: Reflux nephropathy in children
submitted to unilateral nephrectomy: A clinicopathological study. Clin
Nephrol 40: 308–314, 1993
2. Yeung CK, Godley ML, Dhillon HK, Gordon I, Duffy PG, Ransley PG:
BASIC RESEARCHwww.jasn.org
J Am Soc Nephrol 21: 113–123, 2010 Whole-Genome Linkage and Association Scan in VUR 121
The characteristics of primary vesico-ureteric reflux in male and female
infants with pre-natal hydronephrosis. Br J Urol 80: 319–327, 1997
3. Williams G, Fletcher JT, Alexander SI, Craig JC: Vesicoureteral reflux.
J Am Soc Nephrol 19: 847–862, 2008
4. The Renal Association, UK Renal Registry, The Ninth Annual Report.
Available at: http://www.renalreg.com/Reports/2006.html. Accessed
November 2, 2009
5. Kenda RB, Fettich JJ: Vesicoureteric reflux and renal scars in asymptom-
atic siblings of children with reflux. Arch Intern Med 67: 506–508, 1992
6. Hollowell JG, Greenfield SP: Screening siblings for vesicoureteral
reflux. J Urol 168: 2138–2141, 2002
7. Noe HN, Wyatt RJ, Peeden JN Jr, Rivas ML: The transmission of
vesicoureteral reflux from parent to child. J Urol 148: 1869–1871,
1992
8. Kaefer M, Curran M, Treves ST, Bauer S, Hendren WH, Peters CA,
Atala A, Diamond D, Retik A: Sibling vesicoureteral reflux in multiple
gestation births. Pediatrics 105: 800–804, 2000
9. Feather SA, Malcolm S, Woolf AS, Wright V, Blaydon D, Reid CJ,
Flinter FA, Proesmans W, Devriendt K, Carter J, Warwicker P, Good-
ship TH, Goodship JA: Primary, nonsyndromic vesicoureteric reflux
and its nephropathy is genetically heterogenous, with a locus on
chromosome 1. Am J Hum Genet 66: 1420–1425, 2000
10. Sanna-Cherchi S, Reese A, Hensle T, Caridi G, Izzi C, Kim YY, Konka A,
Murer L, Scolari F, Ravazzolo R, Ghiggeri GM, Gharavi AG: Familial
vesicoureteral reflux: Testing replication of linkage in seven new mul-
tigenerational kindreds. J Am Soc Nephrol 16: 1781–1787, 2005
11. Vats KR, Ishwad C, Singla I, Vats A, Ferrell R, Ellis D, Moritz M, Surti U,
Jayakar P, Frederick DR, Vats AN: A locus for renal malformations
including vesico-ureteric reflux on chromosome 13q33–34. J Am Soc
Nephrol 17: 1158–1167, 2006
12. Conte ML, Bertoli-Avella AM, de Graaf BM, Punzo F, Lama G, La
Manna A, Grassia C, Rambaldi PF, Oostra BA, Perrotta S: A genome
search for primary vesicoureteral reflux shows further evidence for
genetic heterogeneity. Pediatr Nephrol 23: 587–595, 2008
13. Kelly H, Molony C, Darlow JM, Pirker ME, Yoneda A, Green AJ, Puri P,
Barton DE: A genome-wide scan for genes involved in primary vesi-
coureteric reflux. J Med Genet 44: 710–717, 2007
14. Lander E, Kruglak L: Genetic dissection of complex traits: Guidelines
for interpreting and reporting linkage results. Nat Genet 11: 241–247,
1995
15. Weng PL, Sanna-Cherchi S, Hensle T, Shapiro E, Werzberger A, Caridi
G, Izzi C, Konka A, Reese AC, Cheng R, Werzberger S, Schlussel RN,
Burk RD, Lee JH, Ravazzolo R, Scolari F, Ghiggeri GM, Glassberg K,
Gharavi AG: A recessive gene for primary vesicoureteral reflux maps
to chromosome 12p11–q13. J Am Soc Nephrol 20: 1633–1640, 2009
16. Kerecuk L, Schreuder MF, Woolf AS: Renal tract malformations: Per-
spectives for nephrologists. Nat Clin Pract Nephrol 4: 312–325, 2008
17. Kong A, Cox NJ: Allele-sharing models: LOD scores and accurate
linkage tests. Am J Hum Genet 61: 1179–1188, 1997
18. Wellcome Trust Case Control Consortium: Genome-wide association
study of 14,000 cases of seven common diseases and 3,000 shared
controls. Nature 447: 661–678, 2007
19. Huber P: The behaviour of maximum likelihood estimates under non-
standard conditions. In: Proceedings of the Fifth Berkeley Symposium
on Mathematical Statistics and Probability, Vol. I, edited by Le Cam L,
Neyman J, Berkeley, University of California Press, 1967, pp 221–233
20. White H: Maximum likelihood estimation of misspecified models.
Econometrica 50: 1–25, 1982
21. Dudbridge F: Likelihood-based association analysis for nuclear fami-
lies and unrelated subjects with missing genotype data. Hum Hered
66: 87–98, 2008
22. Devlin B, Roeder K, Bacanu SA: Unbiased methods for population-
based association studies. Genet Epidemiol 21: 273–284, 2001
23. Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA,
Tanzi RE, Watkins PC, Ottina K, Wallace MR, Sakaguchi AY, Young
AB, Shoulson I, Bonilla E, Martin JB: A polymorphic DNA marker
genetically linked to Huntingdon’s disease. Nature 306: 234 –238,
1983
24. Kerem B, Rommens JM, Buchana JA, Markiewicz D, Cox TK, Chakra-
varti M, Buchwald M, Tsui LC: Identification of the cystic fibrosis gene:
Genetic analysis. Science 245: 1073–1080, 1989
25. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z,
Zielenski J, Lod S, Plavsic N, Chou J, Drumm ML, Iannuzzi MC, Collins
FS, Tsui L: Identification of the cystic fibrosis gene: Cloning and
characterization of complementary DNA. Science 245: 1066–1072,
1989
26. Rommens J, Iannuzzi M, Kerem BS, Drumm M, Melmer G, Dean M,
Rozmahel R, Cole J, Kennedy D, Hidaka N, Zsiga M, Buchwald M,
Riordan J, Tsui LC, Collins F: Identification of the cystic fibrosis gene:
Chromosome walking and jumping. Science 245: 1059–1065, 1989
27. Abreu PC, Hodge SE, Greenberg DA: Quantification of type I error
probabilities for heterogeneity LOD scores. Genet Epidemiol 22:
156–169, 2002
28. Li B, Leal SM: Methods for detecting associations with rare variants for
common diseases: Application to analysis of sequence data. Am J
Hum Genet 83: 311–321, 2008
29. Ji W, Foo JN, O’Roak BJ, Zhao H, Larson MG, Simon DB, Newton-
Cheh C, State MW, Levy D, Lifton RP: Rare independent mutations in
renal salt handling genes contribute to blood pressure variation. Nat
Genet 40: 592–599, 2008
30. Risch N: Implications of multilocus inheritance for gene-disease asso-
ciation studies. Theoretical Population Biology 60: 215–220, 2008
31. Antoniou AC, Easton DF: Polygenic inheritance of breast cancer:
Implications for design of association studies. Genet Epidemiol 25:
190–202, 2003
32. Howson JM, Barratt BJ, Todd JA, Cordell HJ: Comparison of popu-
lation and family-based methods for genetic association analysis in the
presence of interacting loci. Genet Epidemiol 29: 51–67, 2005
33. Decaillot FM, Rozenfeld R, Gupta A, Devi LA: Cell surface targeting of
m-d opioid receptor heterodimers by RTP4. Proc Natl Acad Sci U S A
105: 16045–16050, 2008
34. Lu W, van Eerde AM, Fan X, Quintero-Rivera F, Kulkarni S, Ferguson
H, Kim HG, Fan Y, Xi Q, Li QG, Sanlaville D, Andrews W, Sundaresan
V, Bi W, Yan J, Giltay JC, Wijmenga C, de Jong TP, Feather SA, Woolf
AS, Rao Y, Lupski JR, Eccles MR, Quade BJ, Gusella JF, Morton CC,
Maas R: Disruption of ROBO2 is associated with urinary tract anoma-
lies and confers risk of vesicoureteral reflux. Am J Hum Genet 80:
616–632, 2007
35. Adalat S, Woolf AS, Johnstone KA, Wirsing A, Harries L, Long DA,
Hennekam RC, Ledermann SE, Rees L, van’t Hoff W, Marks SD,
Trompeter RS, Tullus K, Winyard PJ, Cansick J, Mushtaq I, Dhillon HK,
Bingham C, Edghill EL, Shroff R, Stanescu H, Ryffel GU, Ellard S,
Bockenhauer D: HNF1B mutations associate with hypomagnesemia
and renal magnesium wasting. J Am Soc Nephrol 20: 1123–1131,
2009
36. Yim HE, Jung MJ, Choi BM, Bae IS, Yoo KH, Hong YS, Lee JW, Kim SK:
Genetic polymorphism of the renin-angiotensin system on the devel-
opment of primary vesicoureteral reflux. Am J Nephrol 24: 178–187,
2004
37. Hohenfellner K, Hunley TE, Yerkes E, Habermehl P, Hohenfellner R,
Kon V: Angiotensin II, type 2 receptor in the development of vesico-
ureteric reflux. BJU Int 83: 318–322, 1999
38. Yoneda A, Cascio S, Green A, Barton D, Puri P: Angiotensin II type 2
receptor gene is not responsible for familial vesicoureteral reflux.
J Urol 168: 1138–1141, 2002
39. Yang Y, Houle AM, Letendre J, Richter A: RET Gly691Ser mutation is
associated with primary vesicoureteral reflux in the French-Canadian
population from Quebec. Hum Mutat 29: 695–702, 2008
40. Darlow JM, Molloy NH, Green AJ, Puri P, Barton DE: The increased
incidence of the RET p.Gly691Ser variant in French-Canadian vesi-
coureteric reflux patients is not replicated by a larger study in Ireland.
Hum Mutat 30: E612–E617, 2009
BASIC RESEARCH www.jasn.org
122 Journal of the American Society of Nephrology J Am Soc Nephrol 21: 113–123, 2010
41. Jiang S, Gitlin J, Deng FM, Liang FX, Lee A, Atala A, Bauer SB, Ehrlich
GD, Feather SA, Goldberg JD, Goodship JA, Goodship TH, Hermanns
M, Hu FZ, Jones KE, Malcolm S, Mendelsohn C, Preston RA, Retik AB,
Schneck FX, Wright V, Ye XY, Woolf AS, Wu XR, Ostrer H, Shapiro E,
Yu J, Sun TT: Lack of major involvement of human uroplakin genes in
vesicoureteral reflux: Implications for disease heterogeneity. Kidney
Int 66: 10–19, 2004
42. Barrett JC, Cardon LR: Evaluating coverage of genome-wide associ-
ation studies. Nat Genet 38: 659–662, 2006
43. Korn JM, Kuruvilla FG, McCarroll SA, Wysoker A, Nemesh J, Cawley S,
Hubbell E, Veitch J, Collins PJ, Darvishi K, Lee C, Nizzari MM, Gabriel
SB, Purcell S, Daly MJ, Altshuler D: Integrated genotype calling and
association analysis of SNPs, common copy number polymorphisms
and rare CNVs. Nat Genet 40: 1253–1260, 2008
44. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D,
Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N,
Ahmed S, Healey CS, Bowman R, SEARCH collaborators, Meyer KB,
Haiman CA, Kolonel LK, Henderson BE, Marchand LL, Brennan P,
Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC,
Eccles D, Evans DG, Peto J, Fletcher O, Johnson N, Seal S, Stratton
MR, Rahman N, Chenevix-Trench G, G SEBB, Nordestgaard, Axelsson
CK, Garcia-Closas M, Brinton L, Chanock S, Lissowska J, Peplonska B,
Nevanlinna H, Fagerholm R, Eerola H, Kang D, Yoo KY, Noh DY, Ahn
SH, Hunter DJ, Hankinson SE, Cox DG, Hall P, Wedren S, Liu J, Low
YL, Bogdanova N, Schurmann P, Dork T, Tollenaar RA, Jacobi CE,
Devilee P, Klijn JG, Sigurdson AJ, Doody MM, Alexander BH, Zhang
J, Cox A, Brock IW, MacPherson G, Reed MW, Couch FJ, Goode EL,
Olson JE, Meijers-Heijboer H, van den Ouweland A, Uitterlinden A,
Rivadeneira F, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Hopper
JL, McCredie M, Southey M, Giles GG, Schroen C, Justenhoven C,
Brauch H, Hamann U, Ko YD, Spurdle AB, Beesley J, Chen X, kCon-
Fab, AOCS Management Group, Mannermaa A, Kosma VM, Kataja V,
Hartikainen J, Day NE, Cox DR, Ponder BA: Genome-wide association
study identifies novel breast cancer susceptibility loci. Nature 447:
1087–1093, 2007
45. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM,
Lindgren CM, Perry JR, Elliott KS, Lango H, Rayner NW, Shields B,
Harries LW, Barrett JC, Ellard S, Groves CJ, Knight B, Patch AM, Ness
AR, Ebrahim S, Lawlor DA, Ring SM, Ben-Shlomo Y, Jarvelin MR, Sovio
U, Bennett AJ, Melzer D, Ferrucci L, Loos RJ, Barroso I, Wareham NJ,
Karpe F, Owen KR, Cardon LR, Walker M, Hitman GA, Palmer CN,
Doney AS, Morris AD, Smith GD, Hattersley AT, McCarthy MI: A
common variant in the FTO gene is associated with body mass index
and predisposes to childhood and adult obesity. Science 316: 889–
894, 2007
46. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango
H, Timpson NJ, Perry JR, Rayner NW, Freathy RM, Barrett JC, Shields
B, Morris AP, Ellard S, Groves CJ, Harries LW, Marchini JL, Owen KR,
Knight B, Cardon LR, Walker M, Hitman GA, Morris AD, Doney AS,
Wellcome Trust Case Control Consortium (WTCCC), McCarthy MI,
Hattersley AT: Replication of genome-wide association signals in UK
samples reveals risk loci for type 2 diabetes [published erratum ap-
pears in Science 317: 1035–1036, 2007]. Science 316: 1336–1341,
2007
47. Todd J, Walker N, Cooper J, Smyth D, Downes K, Plagnol V, Bailey R,
Nejentsev S, Field S, Payne F, Lowe C, Szeszko J, Hafler J, Zeitels L,
Yang J, Vella A, Nutland S, Stevens H, Schuilenburg H, Coleman G,
Maisuria M, Meadows W, Smink L, Healy B, Burren O, Lam A, Oving-
ton N, Allen J, Adlem E, Leung H, Wallace C, Howson J, Guja C,
Ionescu-Tirgoviste C, Genetics of Type 1 Diabetes in Finland, Sim-
monds M, Heward J, Gough S, Wellcome Trust Case Control Consor-
tium, Dunger D, Wicker L, Clayton D: Robust associations of four new
chromosome regions from genome-wide analyses of type 1 diabetes.
Nat Genet 39: 857–864, 2007
48. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M,
Zhang K, Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, Luca AD,
Easterbrook P, Francioli P, Mallal S, Martinez-Picado J, Miro JM, Obel
N, Smith JP, Wyniger J, Descombes P, Antonarakis SE, Letvin NL,
McMichael AJ, Haynes BF, Telenti A, Goldstein DB: A whole-genome
association study of major determinants for host control of HIV-1.
Science 317: 944–947, 2007
49. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, de Bakker
PI, Abecasis GR, Almgren P, Andersen G, Ardlie K, Bostro¨m KB,
Bergman RN, Bonnycastle LL, Borch-Johnsen K, Burtt NP, Chen H,
Chines PS, Daly MJ, Deodhar P, Ding CJ, Doney AS, Duren WL, Elliott
KS, Erdos MR, Frayling TM, Freathy RM, Gianniny L, Grallert H, Grarup
N, Groves CJ, Guiducci C, Hansen T, Herder C, Hitman GA, Hughes
TE, Isomaa B, Jackson AU, Jørgensen T, Kong A, Kubalanza K, Kuru-
villa FG, Kuusisto J, Langenberg C, Lango H, Lauritzen T, Li Y,
Lindgren CM, Lyssenko V, Marvelle AF, Meisinger C, Midthjell K,
Mohlke KL, Morken MA, Morris AD, Narisu N, Nilsson P, Owen KR,
Palmer CN, Payne F, Perry JR, Pettersen E, Platou C, Prokopenko I, Qi
L, Qin L, Rayner NW, Rees M, Roix JJ, Sandbaek A, Shields B, Sjo¨gren
M, Steinthorsdottir V, Stringham HM, Swift AJ, Thorleifsson G, Thor-
steinsdottir U, Timpson NJ, Tuomi T, Tuomilehto J, Walker M, Wa-
tanabe RM, Weedon MN, Willer CJ, Wellcome Trust Case Control
Consortium, Illig T, Hveem K, Hu FB, Laakso M, Stefansson K, Ped-
ersen O, Wareham NJ, Barroso I, Hattersley AT, Collins FS, Groop L,
McCarthy MI, Boehnke M, Altshuler D: Meta-analysis of genome-wide
association data and large-scale replication identifies additional sus-
ceptibility loci for type 2 diabetes. Nat Genet 40: 638–645, 2008
50. Darge K: Voiding urosonography with US contrast agents for the
diagnosis of vesicoureteric reflux in children II: Comparison with ra-
diological examinations. Pediatr Radiol 38: 54–63, 2008
51. Abecasis GR, Cherney SS, Cookson WO, Cardon LR: Merlin-rapid
analysis of dense genetic maps using sparse gene flow trees. Nat
Genet 30: 97–101, 2002
52. Spielman RS, McGinnis RE, Ewens WJ: Transmission test for linkage
disequilibrium: The insulin gene region and insulin-dependent diabe-
tes mellitus. Am J Hum Genet 52: 506–516, 1993
53. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich
D: Principal components analysis corrects for stratification in genome-
wide association studies. Nat Genet 38: 904–909, 2006
54. Clayton D: Testing for association on the X chromosome. Biostatistics
9: 593–600, 2008
Supplemental information for this article is available online at http://www.
jasn.org/.
BASIC RESEARCHwww.jasn.org
J Am Soc Nephrol 21: 113–123, 2010 Whole-Genome Linkage and Association Scan in VUR 123
